Compare Lemonade Inc (LMND) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Lemonade Inc trades at $46.5 (market cap $3.63B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 16.2× Lemonade Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| LMND | TAK | |
|---|---|---|
Market Cap | $3.63B | $58.74B |
Volume | 1,544,794 | 3,110,994 |
Sector | Financials | Health |
52-Week High | $96.57 | $19.05 |
52-Week Low | $43.91 | $13.23 |
Typical Hold Time | 27 Days | 1 Days |
Enterprise Value | $3.49B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LMND trades at $46.64, down 0.41% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains strong at 32% year-over-year in Q2 2026, with improving loss ratios and gross profit up 76%. The company is expanding geographically and expects its first EBITDA-positive quarter in late 2026, supported by AI-driven efficiency gains.
While LMND shows promising growth and path to profitability, the stock faces headwinds from persistent net losses, high valuation multiples, and mixed analyst sentiment. The consensus price target of $67.00 suggests 44% upside potential, but investors must weigh growth prospects against ongoing cash burn and competitive pressures in the insurtech space.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
